Thursday, April 30, 2015

Top 10 Canadian Companies For 2015

Top 10 Canadian Companies For 2015: Enerplus Corporation (ERF)

Enerplus Corporation, together with subsidiaries, engages in the exploration and development of crude oil and natural gas in United States and Canada. As of December 31, 2011, it had 322 MMBOE of proved plus probable reserves. The company also held a portfolio of approximately 380,000 net acres of land comprised of 75,000 net acres at Fort Berthold targeting the Bakken and Three Forks; 65,000 net acres in the Duvernay; 33,000 net acres in the Montney; 67,000 net acres in the Stacked Mannville; 30,000 net acres in the Cardium and other emerging oil plays in Canada; and 110,000 net acres in the Marcellus. In addition, it had 120 gross producing wells. The company was founded in 1986 and is headquartered in Calgary, Canada.

Advisors' Opinion:
  • [By Dan Caplinger]

    The biggest worry that some investors have about Pengrowth is that its dividend is large compared to its earnings. Similar issues forced Penn West Petroleum (NYSE: PWE  ) , also a former Canroy, to cut its dividend a couple months ago. Although extraordinary measures have helped Pengrowth and Enerplus (NYSE: ERF  ) sustain payouts at levels that were last reduced in the middle of 2012, both companies could eventually see further pressure on their payouts in future.

  • [By Rich Duprey]

    Canadian oil and gas producer Enerplus (NYSE: ERF  ) announced today its August monthly dividend of $0.09 Canadian per share, which is equivalent to $0.09 U.S. per share at an exchange rate of 0.9674.

  • [By Rich Duprey]

    Canadian oil and gas producerEnerplus (NYSE: ERF  ) announced yesterdayits June monthly dividend of $0.09 Canadian per share, which is equivalent to $0.09 U.S. per share at an exchange rate of 0.9699.

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-canadian-companies! -for-2015-4.html

Wednesday, April 29, 2015

Top High Dividend Companies To Watch For 2015

Top High Dividend Companies To Watch For 2015: Maui Land & Pineapple Company Inc. (MLP)

Maui Land & Pineapple Company, Inc., together with its subsidiaries, engages in the development, sale, and leasing of real estate properties. It owns approximately 23,300 acres of land on Maui. The company also offers water and waste transmission services. In addition, it manages certain resort amenities at the Kapalua Resort. The company was founded in 1909 and is based in Lahaina, Hawaii.

Advisors' Opinion:
  • [By Matthew Skelly]

    The technology of fracturing (and the horizontal style of drilling), is changing America's needs on the energy front. At the epicenter of this infrastructure build-out is Atlas Pipeline Partners (NYSE:APL), a midstream gathering and processing company that trades as a Master Limited Partnership, (MLP). Atlas Pipeline is essentially a middle man between the drillers and long-haul transportation pipelines. It gathers mixed volumes of natural gas and natural gas liquids (NGLs) such as ethane, propane, and butanes, etc. from the thousands of wells drilled by its drilling customers, back through pipelines to its processing plants, which will separate the gas from the NGLs. Both are then sold to long-haul transportation pipelines, which take the two products downstream to the next part of the energy supply chain.

  • [By Dividends4Life]

    Sunoco Logistics Partners (SXL) is a master limited partnership (MLP) that was formed by Sunoco Inc. to acquire, own and operate a group of refined product and crude oil pipelines and terminal facilities.
    Yield: 3.6% | Years of Dividend Growth: 11

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-high-dividend-companies-to-watch-for-2015.html

Tuesday, April 28, 2015

Top 10 Value Stocks To Own Right Now

Choosing the right company

It is paramount for an investor to pinpoint the right company. This implies identifying a company which offers growth opportunities. Growth that is not just sustainable but also superior (that is, minimum 20 per cent) as well as profitable.

That is to say, the company should earn a superior return (of not less than 20 per cent) on its shareholders�capital (net worth).

Getting the investment 'time' perspective right

'Time is money' is a one-liner that says it all when it comes to equities! Timing your investment is extremely crucial. In terms of the investment 'time' perspective, in the short-run (typically 3 to 6 months), the performance of equity shares is driven more by market sentiment than by company fundamentals.So, you should invest so that you can participate in and benefit from the company's growth. Keeping this in mind, the ideal period to stay invested should preferably be greater than 5 years.

You would learn that in the long run, the relevance of the right price diminishes. If you choose the right company and have the right time perspective, in the longer term, it doesn't really matter too much whether you bought it at the lowest (right) price or not. This is because as long as the company is growing and you hold on to your investment, the Power of Compounding will multiply the value of your investment at a rate that will make the initial investment price insignificant. This makes a real mantra for wealth creation!

Returns you will earn

Top 10 Gas Stocks To Own Right Now: Schlumberger N.V.(SLB)

Schlumberger Limited, together with its subsidiaries, supplies technology, integrated project management, and information solutions to the oil and gas exploration and production industries worldwide. The company?s Oilfield Services segment provides exploration and production services; wireline technology that offers open-hole and cased-hole services; supplies engineering support, directional-drilling, measurement-while-drilling, and logging-while-drilling services; and testing services. This segment also offers well services; supplies well completion services and equipment; artificial lift; data and consulting services; geo services; and information solutions, such as consulting, software, information management system, and IT infrastructure services that support oil and gas industry. Its WesternGeco segment provides reservoir imaging, monitoring, and development services; and operates data processing centers and multiclient seismic library. This segment also offers variou s services include 3D and time-lapse (4D) seismic surveys to multi-component surveys for delineating prospects and reservoir management. The company?s M-I SWACO segment supplies drilling fluid systems to improve drilling performance; fluid systems and specialty tools to optimize wellbore productivity; production technology solutions to maximize production rates; and environmental solutions that manages waste volumes generated in drilling and production operations. Its Smith Oilfield segment designs, manufactures, and markets drill bits and borehole enlargement tools; and supplies drilling tools and services, tubular, completion services, and other related downhole solutions. The company?s Distribution segment markets pipes, valves, and fittings, as well as mill, safety, and other maintenance products. This segment also provides warehouse management, vendor integration, and inventory management services. Schlumberger Limited was founded in 1927 and is based in Houston, Texas.

Advisors' Opinion:
  • [By Lee Jackson]

    Schlumberger Ltd. (NYSE: SLB) is a top mega cap oil field services stock rated as an Overweight at Baird. Strong offshore drilling activity combined with a seasonal rebound in western Canadian activity have driven Schlumberger’s recent growth. The company said it expects double-digit earnings growth for the rest of the year when it reported earnings recently. For 2014 and beyond, Schlumberger sees five markets providing strong growth: Russia, Sub-Saharan Africa, the Middle East, China and Australia. Shareholders are paid a 1.8% dividend. The consensus price target is $110.83. Schlumberger closed Thursday at $91.11.

  • [By David Smith]

    Big and not so big at your service
    In the services sector, perhaps the most difficult to comprehend of the sub-sectors, you likely have a good handle on the kingpin, Schlumberger (NYSE: SLB  ) . The company, with a $100 billion market cap, operates in about 85 countries, through the efforts of more than 100,000 employees. Its services include everything from soup to nuts, or seismic to production assistance. So, if you're looking for an ideal company to constitute a single proxy for the services contingent, Schlumberger's a good bet.

Top 10 Value Stocks To Own Right Now: Tupperware Corporation(TUP)

Tupperware Brands Corporation operates as a direct seller of various products across a range of brands and categories through an independent sales force. The company engages in the manufacture and sale of kitchen and home products, and beauty and personal care products. It offers preparation, storage, and serving solutions for the kitchen and home, as well as kitchen cookware and tools, children?s educational toys, microwave products, and gifts under the Tupperware brand name primarily in Europe, Africa, the Middle East, the Asia Pacific, and North America. The company provides beauty and personal care products, which include skin care products, cosmetics, bath and body care, toiletries, fragrances, nutritional products, apparel, and related products principally in Mexico, South Africa, the Philippines, Australia, and Uruguay. It offers beauty and personal care products under the Armand Dupree, Avroy Shlain, BeautiControl, Fuller, NaturCare, Nutrimetics, Nuvo, and Swissgar de brand names. The company sells its Tupperware products directly to distributors, directors, managers, and dealers; and beauty products primarily through consultants and directors. As of December 26, 2009, the Tupperware distribution system had approximately 1,800 distributors, 61,300 managers, and 1.3 million dealers; and the sales force representing the Beauty businesses approximately 1.1 million. The company was formerly known as Tupperware Corporation and changed its name to Tupperware Brands Corporation in December 2005. The company was founded in 1996 and is headquartered in Orlando, Florida.

Advisors' Opinion:
  • [By Arie Goren]

    After running this screen on May 21, 2013, before the markets' open, I discovered the following eight stocks: Sunoco Logistics Partners LP (SXL), Leggett & Platt Inc (LEG), Copa Holdings SA (CPA), RPC Inc. (RES), Tupperware Brands Corp. (TUP), Herbalife Ltd. (HLF), John Wiley & Sons Inc. (JW.A) and C.H. Robinson Worldwide Inc. (CHRW).

  • [By Brian Pacampara]

    Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, household products company Tupperware Brands (NYSE: TUP  ) has earned a coveted five-star ranking.

Top 10 Value Stocks To Own Right Now: Dollar Tree Inc.(DLTR)

Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise primarily at the fixed price of $1.00. The company operates its stores under the names of Dollar Tree, Deal$, Dollar Tree Deal$, Dollar Giant, and Dollar Bills. Its stores offer consumable merchandise, including candy and food, and health and beauty care, as well as household consumables, such as paper, plastics, household chemicals, in select stores, and frozen and refrigerated food; variety merchandise, which includes toys, durable housewares, gifts, party goods, greeting cards, softlines, and other items; and seasonal goods, such as Easter, Halloween, and Christmas merchandise. As of April 30, 2011, it operated 4,089 stores in 48 states and the District of Columbia, as well as 88 stores in Canada. The company was founded in 1986 and is based in Chesapeake, Virginia.

Advisors' Opinion:
  • [By Mani]

    Dollar Tree, Inc. (NASDAQ:DLTR) is one of the companies that are set to exploit the ongoing trend of consumers' increasing focus on value with significant opportunity to grow its store base, and expand margins.

  • [By Ben Levisohn]

    Shares of Supervalu have dropped 8.3% to $6.31 at 2:59 p.m., within spitting distance of Goldman’s $6 target price, while competitors Family Dollar Stores (FDO) has gained 0.2% to $70.16,�Dollar General�(DG) has fallen 0.4% t0 $59.02,�Dollar Tree (DLTR) is off 1% to $59.33 and Wal-Mart (WMT) is little changed at $79.19.

  • [By Victor Reklaitis]

    Today�� movers & shakers: Retailers have dropped in the wake of disappointing quarterly results or outlooks. Target Corp. (TGT) �was down 4% after posting weaker margins and earnings at its U.S. business, while Dollar Tree Inc. (DLTR) �dropped 4% after its earnings fell in the third quarter. Read more in the Movers & Shakers column.

  • [By Rich Duprey]

    Deep discounter Dollar Tree (NASDAQ: DLTR  ) announced today that its current chief operating officer, Gary Philbin, will now also carry the title of president, a position previously held by company CEO Bob Sasser.

Top 10 Value Stocks To Own Right Now: Caterpillar Inc.(CAT)

Caterpillar Inc. manufactures and sells construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives worldwide. It operates through three lines of businesses: Machinery, Engines, and Financial Products. The Machinery business offers construction, mining, and forestry machinery, including track and wheel tractors, track and wheel loaders, pipelayers, motor graders, wheel tractor-scrapers, track and wheel excavators, backhoe loaders, log skidders, log loaders, off-highway trucks, articulated trucks, paving products, skid steer loaders, underground mining equipment, tunnel boring equipment, and related parts. It also manufactures diesel-electric locomotives; and manufactures and services rail-related products and logistics services for other companies. The Engines business provides diesel, heavy fuel, and natural gas reciprocating engines for Caterpillar machinery, electric power generation systems, marine, petrol eum, construction, industrial, agricultural, and other applications. It offers industrial turbines and turbine-related services for oil and gas, and power generation applications. This business also remanufactures Caterpillar engines, machines, and engine components; and offers remanufacturing services for other companies. The Financial Products business provides retail and wholesale financing alternatives for Caterpillar machinery and engines, solar gas turbines, and other equipment and marine vessels, as well as offers loans and various forms of insurance to customers and dealers. It also offers financing for vehicles, power generation facilities, and marine vessels. The company markets its products directly, as well as through its distribution centers, dealers, and distributors. It was formerly known as Caterpillar Tractor Co. and changed its name to Caterpillar Inc. in 1986. Caterpillar Inc. was founded in 1925 and is headquartered in Peoria, Illinois.

Advisors' Opinion:
  • [By Jeremy Bowman]

    Caterpillar (NYSE: CAT  ) was the worst performer out of the 30 Dow components, falling 1.5%. Talks between the construction equipment maker and a Milwaukee union fell apart after workers rejected a new contract that would have frozen wages for current employees and paid new employees a lower wage. Shares of Caterpillar had increased more than 10% in the last three weeks so the stock may just be cooling off after its bullish run.

  • [By WALLSTCHEATSHEET]

    Caterpillar is a provider of construction and related industrial products and services during a time where countries around the world are seeing expansion. The stock has not done so well in the last year as it trades at the low-end of an established price range. Over the last four quarters, earnings and revenue figures have been mixed which has surprisingly sat well with investors in the company. Relative to its peers and sector, Caterpillar has been a poor year-to-date performer. WAIT AND SEE what Caterpillar does in coming quarters.

  • [By Mike Deane]

    Before the opening bell on Monday, Caterpillar Inc. (CAT) announced its fourth quarter and full year earnings, posting lower revenue compared to last year’s quarterly and FY results.

    CAT’s Earnings in Brief

    Caterpillar reported fourth quarter revenues of $14.402 billion, down 10% from last year’s Q4 revenue of $16.075 billion. The company’s Q4 profit came in at $1 billion, up from last year’s Q4 profit of $697 million. SWK’s EPS for the quarter was $1.54, up from last year’s Q4 EPS of $1.04. CAT beat analysts’ estimates of $1.28 EPS on revenues of $13.64 billion. For the full year, CAT posted revenues of $55.565 billion, down from $65.875 billion, and profit of $3.789 billion versus last year’s $5.681 billion. For the FY2014, CAT expects EPS of $5.85.

    CEO Commentary

    Caterpillar’s chairman and CEO Doug Oberhelman had the following comments about the company’s earnings:�”In such a challenging environment, I am proud of the way our employees came together in 2013. Despite a sales and revenues decline of about $10 billion, we set a record for operating cash flow, strengthened our balance sheet and improved our overall market position for machines. We continued to improve safety in our facilities and the quality of the products we ship each day. Cost flexibility is critical to our strategy and was a significant focus in 2013 as we took substantial actions to help maintain profitability as sales declined. Excluding the impact of cost absorption our�manufacturing costs�and SG&A and R&D expenses were favorable by $1.2 billion compared with 2012. It wasn’t easy, especially for our employees who endured an incredibly tough year, but the actions we initiated helped us deliver strong operational performance in 2013.”

    CAT’s Dividend and Stock Buyback

    Caterpillar did not announced any changes to its dividend in its earnings report. The compa

  • [By DAG1996]

    Opportunity Highlights:

    The market is overreacting to recent company-specific news.Coinciding market weakness is likely to present a buying opportunity.Forward P/E = 11.87Next 5-year annual EPS growth estimate >41%.Manitowoc 24% gross margin [ttm] is the highest in the Heavy Machinery & Vehicles industry and is growing.In Q2, Manitowoc Crane revenue grew 7.6% year over year, while competitor Terex (TEX) crane revenue grew only 3.2% and Caterpillar (CAT) construction business revenue declined 9%.Morgan Stanley notes: "We believe that Manitowoc can add 12% and 31% upside to EPS in the event of a modest and robust non-residential construction recovery, respectively."Stifel Nicolaus rates Manitowoc a "buy" with a $25 price target.

    Why is there an opportunity in Manitowoc shares?

Hot Biotech Companies To Invest In 2014

On paper, Oncothyreon Inc. (NASDAQ:ONTY) doesn't look like a particularly compelling investment. The pre-revenue biotech company is poised to keep booking sizable losses as it continues to work on its lung cancer drug tecemotide (formerly Stimuvax), which has rejected by the FDA last year but is still being reworked for a slightly different illness than was being targeted initially. And, with no other Phase 3 drug in its pipeline, traders may be rightfully wondering if there's any real catalyst for ONTY in the foreseeable future.

The doubts nagging ONTY even make sense... basically. As is the case with so may other biotech stocks though, Oncothyreon is a case where we need to pat close attention to what the market is telling us about the stock rather than the headlines. After all, it's the collective of traders that determine a stock's price - via the bidding process - and not the company's fiscal performance itself. If the market sees enough upside in ONTY, then technically speaking, it IS at least a good trade.

Top 5 Retail Companies To Watch For 2015: ImmunoCellular Therapeutics Ltd (IMUC)

ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�� own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�� products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�� immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

The Company in addition to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients��tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.

The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.

Advisors' Opinion:
  • [By Lauren Pollock]

    ImmunoCellular Therapeutics Ltd.(IMUC) said its leading product candidate, a dendritic cell-based vaccine for brain cancer, didn’t show a statistically significant advantage in overall survival in a Phase II study. In a research note, Maxim Group said it is pushing its EU approval date target to 2019 and lowered its estimate on the stock to $12 a share from $18 a share. The stock plunged 62% to $1.04 premarket.

  • [By Monica Gerson]

    ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular's trailing-twelve-month ROE is -59.80%.

    Posted-In: market losersNews Movers & Shakers Intraday Update Markets

  • [By Smith On Stocks]

    Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.

Hot Biotech Companies To Invest In 2014: Bellicum Pharmaceuticals Inc (BLCM)

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company�� product pipeline includes clinical product candidates, such as BPX-501, which is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation; BPX-201, which is a dendritic cell cancer vaccine; and Preclinical product candidates, including BPX-701, which is a T cell receptor (TCR) product candidate for solid tumors; BPX-401, which is a CAR-T product candidate for hematological cancers that express the CD19 antigen, and BPX-601, which is a TCR product candidate for solid tumors expressing the preferentially-expressed antigen in melanoma (PRAME). The Company�� Chemical Induction of Dimerization (CID) technology platform engineers and controls components of the immune system in real time.

CaspaCIDe

CaspaCIDe is the Company�� Chemical Induction of Dimerization (CID) safety switch technology. The CaspaCIDe eliminates cells in the event of toxicity. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9 (iCasp9), an enzyme that is part of the apoptotic pathway. The infusion of rimiducid triggers activation of this domain of caspase-9, which in turn leads to selective apoptosis of the CaspaCIDe-containing cells. The CaspaCIDe technology is applied to its lead clinical product candidate, BPX-501 and to its TCR product candidate, BPX-701.

The CaspaCIDe technology has demonstrated clinical efficacy in human patients beginning as soon as 30 minutes after administration of the activating drug, rimiducid. In the preclinical studies, rimiducid reduced or eliminated CaspaCIDe-containing cells in a dosage dependent manner. The National Cancer Institute is conducting a Phase I/II clinical trial for sarcoma! and other solid tumors with a chimeric antigen receptor (CAR) construct targeting a solid tumor antigen combined with CaspaCIDe.

CIDeCAR

CIDeCAR Technology consists of a CAR T cell that incorporates its co-stimulatory domain, MC, for improved T-cell activation and proliferation, and the CaspaCIDe safety switch. CAR interaction with cancer cell antigens leads to MC signaling, which then leads to activation of T cells. In the event of serious toxicity, rimiducid activation of caspase-9 eliminates the CIDeCAR T cells.

The Company has conducted proof-of-principle preclinical studies for CIDeCAR technology, CIDeCAR candidate BPX-401 and CIDeCAR solid tumor CAR targeting Her2, in which, both were evaluated in vitro. These preclinical studies demonstrated that CIDeCAR technology results in enhanced activation, proliferation and tumor cell killing; and the elimination of these CIDeCAR T cells after exposure to rimiducid.

GoCAR-T

The Company�� GoCAR-T technology incorporates a switch that activates CAR T cells when triggered by both rimiducid and the targeted antigen expressed on the surface of the cancer cells. The GoCAR-T technology separates the CIDeCAR dual co-stimulatory domain, MC, from the antigen recognition domain and moves it onto a separate molecular switch that can be controlled by rimiducid. GoCAR-T cells can only be fully activated when exposed to both the cancer cells and rimiducid. This separation controls the degree of activation of the CAR T cells through adjustments to the amount of rimiducid administered, but still in a tumor-dependent manner.

The Company conducted a proof-of-principle in vitro study for GoCAR-T technology, in which it demonstrated that the GoCAR-T cells targeting the PSCA antigen can only be fully activated, as evidenced by production of IL-2 (left panel) and T-cell proliferation (right panel) when the GoCAR-T cells are exposed to both their target PSCA-expressing human pancreatic cancer cells ! and rimid! ucid. In further in vivo studies of GoCAR-T technology, target antigen PSCA-expressing Capan-1 human pancreatic tumors were established in immune-deficient, or NSG, mice. After seven days, five mice received control T cells modified only with firefly luciferase, an imaging protein, and 10 mice received T cells modified with MC in the form of a molecular switch or iMC, plus a PSCA. CAR (together, BPX-601) and firefly luciferase. Five mice in this second group also received 5 mg/kg rimiducid weekly. T-cell imaging clearly demonstrated that GoCAR-T cells can be stimulated to proliferate in vivo when exposed to target antigen-expressing cancer cells by rimiducid administration.

DeCIDe

The DeCIDe technology is used to control the activation of dendritic cells. The DeCIDe technology couples the signaling domains of CD40 and MyD88 to its CID binding domain, to create inducible MC switch, which is then insert into dendritic cells along with the PSMA antigen to take control of the activation of the dendritic cells and the resulting immune response to cancer. Upon exposure to rimiducid, DeCIDe-containing dendritic cells become highly activated. The DeCIDe technology activates dendritic cells with rimiducid after the patient has been vaccinated and the dendritic cells have migrated to the draining lymph nodes.

The cultured BPX-201 cells transduced with DeCIDe switch technology produce supra-normal levels of IL-12 in response to rimiducid. These data demonstrates that, in addition to the temporal control of dendritic cell activation that DeCIDe technology affords, once exposed to rimiducid, DeCIDe-containing dendritic cells become highly activated, which may lead to more potent anti-cancer activity in patients.

BPX-501

The Company�� CaspaCIDe product candidate BPX-501, is under development for the treatment of hematological diseases. BPX-501 is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation (HSCT), us! ing donor! stem cells. The BPX-501 eliminates donor T cells through the triggering of the CaspaCIDe safety switch upon emergence of Graft-versus-host disease (GvHD). The BPX-501 improves stem cell engraftment and accelerates immune system recovery, while providing for resolution of GvHD. The BPX-501 has a range of applications: an add-back of donor T cells administered to accelerate immune system recovery after allogeneic haplo-HSCT in which the T cells in the transplanted stem cells were depleted, and a donor T-cell infusion administered to prevent or treat relapse of underlying disease after allogeneic HSCT independent of donor match.

The product has undergone a 10-patient Phase I clinical trial with CaspaCIDe modified T cells. Four patients developed GvHD after donor T-cell infusion. A single dosage of rimiducid eliminated around 90% of the modified T cells and resolved GvHD in all four patients without recurrence of GvHD. In the second clinical trial of CaspaCIDe-modified T cells, these demonstrations have been replicated in preliminary data from three patients. BPX-501 is being evaluated in multiple Phase I/II clinical trials in the United States, which includes BP-001, a clinical trial in adults and and BP-003, a clinical trial in children. During the BP-001 clinical trial, BPX-501 is administered after initial allogeneic HSCT for hematological cancers. The BP-003 clinical trial in children with orphan inherited blood disorders includes the administration of BPX-501 after initial allogeneic HSCT. The Company also initiated an additional Phase I/II clinical trial, BPX-004 in children with hematological cancers or orphan inherited blood disorders.

BPX-201

The Company�� product candidate under development, BPX-201 is a dendritic cell cancer vaccine intended to treat metastatic castrate-resistant prostate cancer (mCRPC). BPX-201 is an autologous therapy, in which the patient�� own white blood cells are extracted and modified ex vivo. The cells are matured and then gen! etically ! engineered to express the DeCIDe switch domains and the prostate-specific membrane antigen (PSMA) antigen. The modified cells are then washed, apportioned into individual dosages, and frozen for later administration to the patient. The incorporation of the DeCIDe switch in the presence of rimiducid activates the therapy.

The Company is evaluating BPX-201 in an 18-patient Phase I clinical trial for mCRPC. It is evaluating opportunities for BPX-201 in combination with other cancer immunotherapies, such as checkpoint inhibitors.

BPX-701

The Company�� CaspaCIDe T cell receptor (TCR) Product Candidate, BPX-701 is under development for the treatment of Solid Tumors. BPX-701 is a TCR-based therapy for the treatment of PRAME-expressing melanoma, sarcomas and neuroblastomas. BPX-701 is designed to target preferentially-expressed antigen in melanoma (PRAMEa gene) that is predominantly expressed in human melanomas but not in normal tissues.

The BPX-701 has demonstrated complete elimination in response to rimiducid. The Clinical Cancer Research 2011 has demonstrated that PRAME-specific clones showed high reactivity against a panel of PRAME positive tumor cell lines, metastatic melanoma, sarcomas and neuroblastoma tissues, and no reactivity against normal cell types, with the exception of low reactivity against kidney epithelial cells and intermediate reactivity against mature dendritic cells. The vitro studies demonstrated BPX-701�� affinity to panels of cancer cells presenting PRAME peptides and low affinity to non-tumor cells. In other in vitro studies, rimiducid administration has proved the ability to eliminate BPX-701 cells.

BPX-401

The Company�� CIDeCAR Product Candidate under development, BPX-401, is developed for the treatment of Hematological Cancers, such as acute lymphotcytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and certain types of non-Hodgkin�� lymphoma. The CIDeCAR consists of CAR T cells modified to! include ! its CaspaCIDe safety switch and in which the CAR incorporates the signaling domains of two proteins, MyD88 and CD40. These proteins form the Company�� dual co-stimulatory domain, MC, which is designed to activate T cells in the presence of cancer cells. The Company has generated preclinical proof-of-principle data in vitro signifying that BPX-401 has CAR T cell activation and proliferation potential, and may be effective in killing cancer cells.

BPX-601

The Company�� GoCAR-T Product Candidate, BPX-601, is proposed for the treatment of Solid Tumors. The BPX-601 is undergoing preclinical studies for the treatment of solid tumors overexpressing the prostate stem cell antigen (PSCA), such as some prostate, pancreatic, bladder, esophageal and gastric cancers. The Company�� GoCAR-T technology consists of CAR and T cells. GoCAR-T controls activation and proliferation of the CAR T cells through the scheduled administration of a course of rimiducid infusions.

BPX-601 is undergoing preclinical studies for the treatment of solid tumors overexpressing the PSCA antigen. The Company has demonstrated positive proof-of-principle data in an animal pancreatic tumor model.

The Company competes with Adaptimmune Limited, bluebird bio, Inc., Celgene Corporation, Cellectis SA, GlaxoSmithKline plc, Intrexon Corporation, Juno Therapeutics, Inc., Kite Pharma, Inc., Novartis AG and Pfizer Inc.

Advisors' Opinion:
  • [By John Udovich]

    Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.

Hot Biotech Companies To Invest In 2014: Tauriga Sciences Inc (TAUG)

Tauriga Sciences, Inc., formerly Immunovative, Inc., incorporated on April 18, 2001, is a development-stage company. The Company along with Constellation Diagnostics, Inc. (Constellation) focuses on establishing a joint venture partnership to develop and commercialize a imaging-based diagnostic technology for use in predictive and preventative oncology.

The Company has rights to commercialize AlloStim and AlloVax. As of March 31, 2013 the Company did not have any revenues.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap marijuana stocks IMD Companies Inc (OTCMKTS: ICBU), Tauriga Sciences Inc (OTCMKTS: TAUG), ML Capital Group Inc (OTCBB: MLCG) and Lexaria Corp (OTCMKTS: LXRP) are aiming to give investors a high with their latest news. However, only one of these small cap marijuana stocks appears to be the subject of minor paid promotion or investor relations type of activities. So will investors and traders alike get a high off of these small caps? Here is a quick reality check:

  • [By Peter Graham]

    Small cap health care or personal care stocks Axxess Pharma Inc (OTCMKTS: AXXE), Radiant Creations Group Inc (OTCBB: RCGP) and Tauriga Sciences Inc (OTCMKTS: TAUG) have recently been attracting attention in various investment newsletters or in investor alerts. Some of the attention may have to do with paid promotions that two of these small caps have been the subject of. So how healthy are these three small cap health care or personal care orientated stocks? Here is a checkup:

Hot Biotech Companies To Invest In 2014: Cubist Pharmaceuticals Inc.(CBST)

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous, antibiotic with activity against gram-positive organisms, including methicillin-resistant staphylococcus aureus. Its clinical development product pipeline consists of CXA-201, which is in the phase III clinical trial for patients with complicated urinary tract infections; and in phase II clinical trial for patients with complicated abdominal infections. The company is also developing CXA-201 for the treatment of hospital acquired pneumonia. In addition, its product under development comprises CB-183,315, an oral, bactericidal lipopeptide with in vitro bactericidal activity against C. difficile, for the treatment of clostridium difficile-associated diarrhea (CDAD). Further , the company?s pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain. Additionally, it promotes MERREM I.V. (meropenem for injection), a carbapenem class intravenous antibiotic, in the United States under a commercial services agreement with AstraZeneca Pharmaceuticals, LP; and DIFICID as the treatment for CDAD in adults under the co-promotion agreement with Optimer Pharmaceuticals, Inc. The company also has collaborations with Forma Therapeutics, Inc. to discover and develop antibacterial compounds; an agreement with the Broad Institute to transform natural products discovery; a collaboration with Hydra Biosciences, Inc., to develop ion channel drugs; and a collaboration agreement with Alnylam Pharmaceuticals, Inc., for the development and commercialization of Alnylam's RNAi therapeutics as a therapy for the treatment of respiratory syncytial virus. The company was founded in 1992 and is headquartered in Lexington, Mas sachusetts.

Advisors' Opinion:
  • [By Rich Bieglmeier]

    Cubist Pharmaceuticals Inc. (CBST) share price is the beneficiary of an upgrade yesterday. Leerink Swann analyst Marko Kozul believes the biotech is headed to $76.

  • [By Jon C. Ogg]

    Cubist Pharmaceuticals Inc. (NASDAQ: CBST) was raised to Outperform from Market Perform at Leerink Swann.

    Diamondback Energy Inc. (NASDAQ: FANG) was downgraded to Hold from Buy at Canaccord Genuity.

Sunday, April 26, 2015

5 Best Retail Stocks To Own Right Now

5 Best Retail Stocks To Own Right Now: PetSmart Inc(PETM)

PetSmart, Inc., together with its subsidiaries, operates as a specialty retailer of products, services, and solutions for pets in the United States, Puerto Rico, and Canada. The company offers consumables, such as pet food, treats, and litter; and hardgoods, which include pet supplies and other goods comprising collars, leashes, health care supplies, grooming and beauty aids, toys, apparel, and pet beds and carriers, as well as aquariums and habitats, accessories, dcor, and filters for fish, birds, reptiles, and small pets. It also provides fresh-water fish, small birds, reptiles, and small pets; and pet services, such as grooming, including precision cuts, baths, nail trimming and grinding, and teeth brushing, as well as training, boarding, and day camp services. In addition, the company operates PetsHotels that offer boarding for dogs and cats; provides personalized pet care, an on-call veterinarian, temperature controlled rooms and suites, daily specialty treats and p lay time, and day camp services for dogs; and operates veterinary hospitals, which offer services comprising routine examinations and vaccinations, dental care, a pharmacy, and surgical procedures. As of January 29, 2012, it operated 1,232 retail stores; 192 PetsHotels; 791 veterinary hospitals under the trade name of Banfield, The Pet Hospital; and 8 hospitals operated through other third parties in Canada. The company also offers its products through an e-commerce and community site, PetSmart.com. PetSmart, Inc. was founded in 1986 and is based in Phoenix, Arizona.

Advisors' Opinion:
  • [By Rich Duprey]

    There are a lot of moving parts for PetSmart (NASDAQ: PETM  ) going into its annual shareholder meeting on Friday.

    The pet food and supplies leader announced yesterday it has named a new non-executive chairman of the board,Gregory P. Josefowicz, who will assume the role following the meeting. Exiting Chairman and C! EO Bob Moran will not stand for reelection as a director, and company President and COODavid Lenhardt will fill the role of CEO.Executive Vice President Joseph O'Leary will become president and COO. In May, the company named Carrie Teffner as its new chief financial officer.

  • [By Steven Russolillo]

    WATCH FOR: No major economic data on dap. American Eagle, Booz Allen, Eaton Vance(EV), Hormel Foods(HRL), L Brands(LB), Lowe's(LOW), NetApp, PetSmart(PETM), Renren(RENN), Sina, Target, Tiffany, Trina Solar(TSL) and Williams-Sonoma(WSM) are among companies scheduled to report quarterly results.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-retail-stocks-to-own-right-now-2.html

Friday, April 24, 2015

Best Shipping Companies To Buy Right Now

Best Shipping Companies To Buy Right Now: Bio-Reference Laboratories Inc.(BRLI)

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. It offers various chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology, pap smears, tissue pathology, and other tissue analysis. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems. In addition, it operates a Web-based connectivity portal solution for laboratories and physicians to provide laboratory ordering and results to physician customers. The company provides its services directly to physicians, geneticists, hospitals, clinics, and correctional and other health facilities. Bio-Refe rence Laboratories, Inc. was founded in 1981 and is headquartered in Elmwood Park, New Jersey.

Advisors' Opinion:
  • [By Geoff Gannon]

    But if you can definitely hold a company through a tough market that lasts a few years then you can look for a wonderful business to buy and hold at any time. In any market. I found some lovely businesses around the time of the 2000 market peak. They just werent big caps, dot coms, etc. They were smaller more mundane businesses. In at least one case Bio-Reference Labs (BRLI) I made some money (it seemed like a scary big amount at the time) holding the stock for about 2 years but I wouldve made a whole lot more if I had just held that one stock through till today. And even now BRLI seems a fine stock to keep holding. So, you see I couldve saved myself a lot of trouble by holding something for more than 10 years. And it wouldnt have hurt my performance at all. In fact, BRLI has! beaten the market by a lot for a very long time. And, yes, the price I paid for BRLI happens to be the most I ever paid for a stock relative to its record earnings. So, I paid a very high price for a value investor like me for a stock that promptly went on to return around 20% a year for the next 10 years and is now back at almost the exact same P/E ratio where I first bought it.

  • [By Geoff Gannon] strong>DreamWorks (DWA)

    Read these reports. Look for something that might have interested me. Why would Geoff look at DNB, Chuck E. Cheese, etc.? What got him interested in the stock? Do I see the same thing?

    Whenever possible, also read the quarterly earnings call transcripts. You can listen to them too. But its easier if you read them and listen to them.

    Just listening is a bad idea.

    Whenever I can get a transcript of anything even Warren Buffetts appearance on CNBC Ill keep a copy of the transcript even when I have a copy of the video (or audio). You can refer back to a transcript easily. You can highlight. You can take notes.

    Taking Notes

    Now, you are doing those things when reading an annual report, right?

    You never just sit down and read an annual report. You always sit down with a pen, a highlighter, a pad of paper, and a calculator. Use the margins of a 10-K or your pad of paper to jot down notes. As k questions. Do calculations.

    If you ever see a 10-K after Ive read it its not very white anymore. Theres lots of stuff written in the margins. Mostly its questions I was asking myself. But its also calculations of numbers the company does not provide.

    Numbers to Know

    So, for example, in a banks 10-K I always write down:

    路 Deposits per share

    路 Deposits per branch

    路 Cost of deposits

    路 Texas Ratio

    You can actually look up the Texas Ratio of any bank here. And some banks calculate and report cost of deposits the way I like to think about it. But, its not common for banks t! o report ! deposits per branch although small banks will sometimes mention (perhaps in the shareholder letter) what their biggest branch has in deposits. Others may mention how quickly new branches achieved a deposit milestone.

    Those are the kinds of numbers I write in the margins of a banks 10-K. There will be questi ons like: Why is e

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/best-shipping-companies-to-buy-right-now-2.html

Wednesday, April 22, 2015

Hot Net Payout Yield Stocks To Watch Right Now

Investors in the fertilizer industry have something serious to think about. One of the leading nutrient producers, Agrium (NYSE: AGU  ) , is hanging up on two expansion projects -- It has suspended development work on a greenfield project in the U.S. Midwest area, while dropping plans�to expand an existing plant in Alberta.

They weren't just any plans. The projects would have added more than 30% to Agrium's annual nitrogen production capacity, which currently stands at 5.5 million tonnes. Nitrogen is Agrium's primary product and, as the most widely applied nutrient, has tremendous growth potential, particularly in the U.S. More than 50% of the nitrogen consumed in the U.S. last year was comprised of offshore imports. According to Agrium's recent investor presentation, 12 to 14 new nitrogen plants will be needed if the U.S. were to become self-sufficient. So why did Agrium back off its plans despite the opportunities? The answers might surprise you.

Problem of too many
One reason why Agrium put the projects on hold is similar capacity expansion plans by rivals. That might sound as if Agrium is giving in to peer pressure; yet, its concerns may be justified.

Top 10 Defensive Stocks To Buy For 2015: Coinstar Inc.(CSTR)

Coinstar, Inc., through its subsidiaries, provides automated retail solutions primarily in the United States, Canada, Puerto Rico, Ireland, and the United Kingdom. The company owns and operates self-service Redbox kiosks that enable consumers to rent or purchase movies and video games; and self-service coin-counting kiosks where consumers can convert their coin to cash, a gift card, or an E-certificate. It also engages in identifying, evaluating, building, and developing new self-service concepts in the automated retail space, which includes coffee, refurbished electronics, and photo self-service concepts. As of December 31, 2011, the company had 35,400 Redbox kiosks in 29,300 locations and 20,200 coin-counting kiosks in 19,900 locations primarily in supermarkets, drug stores, mass merchants, financial institutions, convenience stores, and restaurants. Coinstar, Inc. was founded in 1991 and is headquartered in Bellevue, Washington.

Advisors' Opinion:
  • [By Canadian Value]

    Position % of Fund Assets 1) First American Financial Corp. (FAF) 7.0% 2) Apple, Inc. (AAPL) 6.5% 3) Coinstar, Inc. (CSTR) 4.8% 4) EMC Corp. (EMC) 4.4% 5) Coach, Inc. (COH) 4.4% 6) Kohl's Corp. (KSS) 4.1% 7) Blucora, Inc. (BCOR) 4.0% 8) Tetra Tech, Inc. (TTEK) 3.1% 9) OM Group, Inc. (OMG) 3.0% 10) American International Group, Inc. (AIG) 2.8% TOTAL 44.1% One area that we believe still offers some value in the market is in high quality, large��ap technology stocks that may be momentarily out��f��avor as they transition from rapid growth to slower growth. In particular, we become interested when that transition is also accompanied by a change in capital allocation policies designed to return more cash to shareholders in the form of dividends and share repurchases. We believe that Apple and EMC are two of the absolute highest quality technology businesses in the world and both have recently announced very material, shareholder��friendly changes to how they will allocate capital.

Hot Net Payout Yield Stocks To Watch Right Now: Opko Health Inc(OPK)

OPKO Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. It provides a range of solutions, including molecular diagnostics tests, proprietary pharmaceuticals, and vaccines to diagnose, treat, and prevent neurological disorders, infectious diseases, oncology, and ophthalmologic diseases. The company offers molecular diagnostic platform technology for the rapid identification of molecules or immunobiomarkers; Alzheimer?s test for Alzheimer?s diagnostic; and protein-based influenza vaccines to provide multi-season and multi-strain protection against various influenza virus strains, such as seasonal influenza strains, as well as global influenza pandemic strains which include swine flu, and avian flu. It also offers Oligonucleotide Therapeutics for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; and oligosaccharide for asthma and chronic obstructive pulmonary diseases. In addition, the company provides Rolapitant, a potent and antagonist; neurokinin-1, which has completed Phase II clinical trials for prevention of chemotherapy induced nausea and vomiting, and post-operative induced nausea and vomiting; and SCH 900978 that has completed Phase II clinical trials for chronic cough. Further, it offers bevasiranib, a drug candidate for the treatment of Wet AMD; and develops Aquashunt, a shunt to be used in the treatment of glaucoma. Additionally, the company involves in the development, commercialization, and sale of ophthalmic diagnostic and imaging systems, and instrumentation products. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Advisors' Opinion:
  • [By James E. Brumley]

    Look out Roche Holding Ltd. (OTCMKTS:RHHBY), and Opko Health Inc. (NYSE:OPK) - you're on notice too. There's a new player in the human growth hormone arena, and it may have built the proverbial better mousetrap. Versartis Inc. (NASDAQ:VSAR) only went public in late March, but with the dust from that IPO settling, it's already becoming clear that VSAR - admittedly a one-trick pony - could pose a real threat to OPK and RHHBY... at least on the human growth hormone front.

  • [By Roberto Pedone]

    Another healthcare player that insiders are jumping into here is Opko Health (OPK), which is a multi-national pharmaceutical and diagnostics company. Insiders are buying this stock into big time strength, since shares are up 76% in 2013.

    Opko Health has a market cap of $3.4 billion and an enterprise value of $3.5 billion. This stock trades at a premium valuation, with a price-to-sales of 38.01 and a price-to-book at 4.01. Its estimated growth rate for this year is -218.2%. This is not a cash-rich company, since the total cash position on its balance sheet is $180.84 million and its total debt is $226.74 million.

    The CEO just bought 19,400 shares, or about $171,000 worth of stock, at $8.79 to $8.90 per share. The same CEO also just bought 13,000 shares, or about $117,000 worth of stock, at $8.99 to $9.04 per share.

    From a technical perspective, OPK is currently trending above its 200-day moving average and below its 50-day moving average, which is neutral trendwise. This stock has been downtrending over the last few weeks, with shares falling from its high of $11.64 to its recent low of $8.17 a share. During that downtrend, shares of OPK have been making mostly lower highs and lower lows, which is bearish technical price action.

    If you're in the bull camp on OPK, then I would look for long-biased trades as long as this stock is trending above its 200-day at $8.31 or above more key support at $8.17, and then once it breaks out above some near-term overhead resistance at $9.20 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 5.53 million shares. If that breakout hits soon, then OPK will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day of $10.06 a share to $11.64 a share.

  • [By GuruFocus]

    SVP & CFO Nimish S Bhatt bought 364 shares of CLMS stock on 11/20/2013 at the average price of 10.47. Nimish S Bhatt owns at least 90,543 shares after this. The price of the stock has increased by 14.52% since.

    Opko Health, Inc. (OPK): CEO & Chairman, 10% Owner Phillip Md Et Al Frost Bought 62,100 Shares

    CEO & Chairman, 10% Owner of Opko Health, Inc. (OPK) Phillip Md Et Al Frost bought 62,100 shares during the past week at an average price of $8.57. Opko Health, Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. Opko Health, Inc. has a market cap of $3.5 billion; its shares were traded at around $8.57 with and P/S ratio of 30.30.

Hot Net Payout Yield Stocks To Watch Right Now: iShares Transportation Average ETF (IYT)

iShares Dow Jones Transportation Average Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones Transportation Average Index (the Index). The Index measures the performance of the transportation sector of the United States equity market, and includes companies in primary groups, such as airlines, trucking, railroads, air freight, transportation services and industrial services.

The Index is subset of the Dow Jones U.S Total Market Index. The components stocks are weighted based on the price of the component securities, with the highest priced securities generally having higher weighting in the Index. The Index is adjusted to reflect changes in capitalization resulting from mergers, acquisitions, stock rights, substitutions and other capital events. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:
  • [By Chad Fraser] 2013 was a strong year for railroad stocks: the iShares Transportation ETF (NYSE: IYT), about the closest you can get to a gauge for the industry (roughly 30% of the fund’s portfolio is devoted to railway operators) gained 39% during the year.

    That’s miles ahead of the Dow Jones Industrials (up 26%) and the S&P 500 (up 29%).

Hot Net Payout Yield Stocks To Watch Right Now: iShares S&P GSCI Commodity-Indexed Trust (GSG)

iShares S&P GSCI Commodity-Indexed Trust (the Trust), formerly iShares GSCI Commodity-Indexed Trust, issues units of beneficial interest, called Shares, representing fractional undivided beneficial interests in its net assets. Substantially all of the assets of the Trust consist of interests in the iShares S&P GSCI Commodity-Indexed Investing Pool LLC (the Investing Pool). The investment objective of the Trust is to seek investment results, through its investment in the Investing Pool, which correspond generally to the performance of the S&P GSCI Total Return Index (the Index). The Investing Pool is a limited liability company. The Investing Pool holds long positions in CERFs, which are futures contracts listed on the Chicago Mercantile Exchange, which have a term of approximately five years after listing and whose settlement at expiration is based on the value of the S&P GSCI Excess Return Index, or S&P GSCI-ER, at that time.

The Index is intended to reflect the performance of a diversified group of commodities. The Index reflects the value of an investment in the S&P GSCI-ER together with a Treasury bill return. The S&P GSCI-ER reflects the returns that are potentially available through a rolling uncollateralized investment in the contracts comprising the S&P GSCI. Barclays Global Investors International, Inc. is the sponsor of the Trust and the manager of the Investing Pool. Barclays Global Investors, N.A. is the trustee of the Trust.

Advisors' Opinion:
  • [By Adam J. Wiederman]

    Getty Images Bitcoin made headlines last year when the value of all outstanding pieces of the electronic currency reached nearly $10 billion. It's not just speculators drawn to the new currency. Many businesses are also attempting to cash in on this growth: Several public companies, including Zynga (ZNGA) and Overstock.com (OSTK), accept Bitcoins as a form of payment. Venture capitalist Marc Andreessen's firm has invested nearly $50 million in Bitcoin-related ventures, and it is looking to invest even more. And the Winklevoss twins -- who notoriously accused Facebook's (FB) Mark Zuckerberg of stealing their idea -- have been "in dialogue" with the SEC about opening the first Bitcoin exchange-traded fund, according to Bloomberg. Yet a new survey from TheStreet.com (TST) reveals that 76 percent of consumers are not familiar with Bitcoin -- and 79 percent would never consider owning a currency like it. Does this signal opportunity for savvy investors? Or is this a fad you'd be wise to avoid? The Basics of Bitcoin Bitcoin is a completely unregulated form of currency developed by an anonymous Japanese programmer (according to some apocryphal claims) as a completely digital, peer-to-peer payment system that is independent of national currencies (which, Bitcoin users argue, are all subject to the riskiness of the underlying country). Bitcoins are rewarded throughout the day to a "Bitcoin miner" whose computer solves a series of algorithms quicker than other miners. The puzzles become more difficult over time, so the calculations take longer and the computations require more computing power. There will eventually be a total of 21 million Bitcoins (12.4 million are in circulation today) and we won't reach the point that they are effectively "mined out" until 2040. The value of a Bitcoin is supposed to be market-driven, meaning they're worth whatever the two parties in a transaction value them as. For example, in one of the original Bitcoin transactions, a "mi

Monday, April 20, 2015

Top 10 Bank Stocks For 2014

Australia�� economy surprised economists by expanding at its fastest pace since late 2012. During the fourth quarter, the country�� gross domestic product grew by 2.8 percent year over year, beating the consensus forecast by a significant three-tenths of a percentage point.

On a seasonally adjusted basis, the economy grew 0.8 percent versus the prior quarter, a tenth of a point better than forecast. And the prior quarter�� year-over-year growth was revised higher, to 2.4 percent.

These results caused a spike in the Australian dollar, which currently trades just below USD0.90, up about 3.5 percent from January�� three-year low. In its latest statement on monetary policy, the Reserve Bank of Australia (RBA), which held short-term rates at their all-time low of 2.5 percent, observed that the exchange rate remains high by historical standards.

In other words, the central bank believes a further decline in the aussie will be necessary to spur economic growth. At the same time, the economy�� stronger-than-expected fourth-quarter performance could keep the RBA in a holding pattern on short-term rates, though according to The Australian economists say the central bank will also be focusing on domestic final demand, which fell 1.2 percent over the past year.

Top 5 Gold Stocks For 2015: Umpqua Holdings Corp (UMPQ)

Umpqua Holdings Corporation (Umpqua) is a financial holding company. Umpqua has two principal operating subsidiaries, Umpqua Bank (the Bank) and Umpqua Investments, Inc. (Umpqua Investments). The Bank is primarily engaged in the business of commercial and retail banking and the delivery of retail brokerage services. The Bank provides a range of banking, wealth management, mortgage banking and other financial services to corporate, institutional and individual customers. Umpqua Investments is a broker-dealer and investment advisor with offices in Portland, Lake Oswego, Medford, Oregon, and in many Umpqua Bank stores. Umpqua Investments offers a range of investment products and services, including stocks, fixed income securities (municipal, corporate, and government bonds, Certificate of Deposits (CDs), and money market instruments), mutual funds, annuities, options, retirement planning, money management services and life insurance. In December 2011, the Bank launched a commercial real estate division. In November 2012, the Company acquired Circle Bancorp, parent company of Circle Bank. In July 2013, Umpqua Holdings Corp completed its acquisition of Financial Pacific Holding Corp.

The Company offers a Switch Kit, which allows a customer to open a primary checking account with Umpqua Bank in less than 10 minutes. Other avenues, through which customers can access its products, include its Website equipped with an e-switchkit, which includes Internet banking through umpqua.online, mobile banking, and its 24-hour telephone voice response system. Umpqua Private Bank serves high net worth individuals with liquid investable assets by providing customized financial solutions and offerings. Umpqua private bank works collaboratively with the Bank�� affiliate retail brokerage Umpqua Investments and with the independent capital management firm Ferguson Wellman Capital Management. Umpqua Investments provides a range of brokerage services, including equity and fixed income products, mutual funds, annui! ties, options, retirement planning and money management services. Additionally, Umpqua Investments offers life insurance policies. At December 31, 2011, Umpqua Investments had 41Series seven-licensed financial advisors serving clients at three stand-alone retail brokerage offices and Investment Opportunity Centers located in many Bank stores.

Lending Activities

Umpqua offers loans for business and commercial customers, including accounts receivable and inventory financing, equipment loans, international trade, real estate construction loans and permanent financing and SBA program financing, as well as capital markets and treasury management. Additionally, it offers designed loan products for small businesses through its Small Business Lending Center. It also has a business banking division to increase lending to small and mid-sized businesses. The Company is also engaged in initiatives that continue to diversify the loan portfolio, including a focus on commercial and industrial loans in addition to financing owner-occupied properties.

Real estate loans are available for construction, purchase and refinancing of residential owner-occupied and rental properties. Borrowers can choose from a variety of fixed and adjustable rate options and terms. It sells residential real estate loans that originate into the secondary market. It also supports the Home Affordable Refinance Program and Home Affordable Modification Program. The Bank also provide loans to individual borrowers for a variety of purposes, including secured and unsecured personal loans, home equity and personal lines of credit and motor vehicle loans. The Bank makes both secured and unsecured loans to individuals and businesses. During 2011, its commercial real estate, commercial, residential, and consumer and other represented approximately 64%, 25%, 10%, and 1%, respectively, of the total non-covered loan and lease portfolio.

Source of Funds

The Company offers an array of deposit p! roducts, ! including non-interest-bearing checking accounts, interest-bearing checking and savings accounts, money market accounts and certificates of deposit. These accounts earn interest at rates established by management based on market factors. It also offers a seniors program to customers over fifty years old, which includes an array of banking services and other amenities, such as purchase discounts, vacation trips and seminars.

Investment Activities

As of December 31, 2011, Umpqua's portfolio of investments securities included securities issued by United States Treasury and agencies, and residential mortgage-backed securities and collateralized mortgage obligations. It also includes obligations of states and political subdivisions, other debt securities, and investments in mutual funds and other equity securities.

Advisors' Opinion:
  • [By Roberto Pedone]

    Umpqua (UMPQ) is engaged in the business of commercial and retail banking and the delivery of retail brokerage services. This stock closed up 5% at $17.11 in Monday's trading session.

    Monday's Volume: 2.16 million

    Three-Month Average Volume: 686,781

    Volume % Change: 235%

    From a technical perspective, UMPQ ripped sharply higher here right off its 50-day moving average of $16.51 with strong upside volume. This move is quickly pushing shares of UMPQ within range of triggering a big breakout trade. That trade will hit if UMPQ manages to take out Monday's intraday high of $17.46 and then once it clears its 52-week high at $17.48 with high volume.

    Traders should now look for long-biased trades in UMPQ as long as it's trending above its 50-day at $16.51 or above more near-term support at $16 and then once it sustains a move or close above those breakout levels with volume that's near or above 686,781 shares. If that breakout hits soon, then UMPQ will set up to enter new 52-week-high territory above, which is bullish technical price action. Some possible upside targets off that breakout are $20 to $23.

Top 10 Bank Stocks For 2014: Barclays PLC (II)

Barclays PLC (Barclays) is a global financial services provider engaged in retail banking, credit cards, wholesale banking, investment banking, wealth management and investment management services. The Company�� operations include its overseas offices, subsidiaries and associates. The Company operates in eight segments: UK Retail and Business Banking (UK RBB), Europe Retail and Business Banking (Europe RBB), Africa Retail and Business Banking (Africa RBB), Barclaycard, Barclays Investment Bank, Barclays Corporate Banking, Wealth and Investment Management, and Head Office and Other Operations. Advisors' Opinion:
  • [By Robert Abbott]

    The company lists competitive factors this way, and in this order in its 10-K: "...(i) vendor and product reputation; (ii) product quality, performance and price; (iii) the availability of software products on multiple platforms; (iv) product scalability; (v) product integration with other enterprise applications; (vi) software functionality and features; (vii) software ease of use; (viii) the quality of professional services, customer support services and training; and (ix) the ability to address specific customer business problems."

  • [By Holly LaFon]

    Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than original cost. As stated in the current prospectus, the Fund�� Investor Class Share�� annual operating expense ratio (gross) is 1.28%. The Fund�� adviser has contractually agreed to waive a portion of its fee and/or reimburse Fund expenses to limit total annual operating expenses at 1.25%, which is in effect until October 31, 2015. Other share classes may vary. The Fund charges a 2.0% redemption fee on shares redeemed within six months of purchase. For the most recent month-end performance, please call (877)328-9437 or visit the Advisor�� website at www.auxierasset.com. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future.Spring 2014 Market CommentaryAuxier Focus Fund�� Investor Class returned a modest 0.25% for the quarter ended March 31, while Standard and Poor�� 500 Stock Index (S&P) rose 1.81%. The Fund ended the quarter with 70% in U.S. stocks, 16% foreign stocks, 1.7 % bonds and 12.3% cash. Since inception in 1999, the Fund�� equity exposure has averaged 72%. Our stockholdings in the healthcare industry generally gained for the quarter. But many of our multinational and foreign stocks were hurt by the threat of currency repercussions from geopolitical events in Russia and Ukraine. The foreign portion of the Fund is easily the most undervalued. Longer term, we see a very favorable risk/reward potential with our UK and European holdings. Some emerging market companies we follow are the cheapest in over twenty years. In allocating capital, we much prefer the gloom of down to flat markets and the corrective process that tempers exuberance. We remember that one of th

  • [By Todd Sullivan]

    HHC has increased all our ownership percentage through the repurchasing of outstanding warrants.

    From the 13D/A
    On December 31, 2013, certain of the Reporting Persons entered into swaps for the benefit of certain Pershing Square Funds. Under the terms of the swaps, (i) the relevant Pershing Square Funds will be obligated to pay to the bank counterparty any negative price performance of the 5,399,839 notional number of Common Shares subject to the swaps as of the expiration date of such swaps, plus interest rates set forth in the applicable contracts, and (ii) the bank counterparty will be obligated to pay the relevant Pershing Square Funds any positive price performance of the 5,399,839 notional number Common Shares subject to the swaps as of the expiration date of the swaps. During the term of the swaps, cash will be paid by the bank counterparty to the relevant Pershing Square Fund in an amount equal to the amount of notional distributions or dividends paid by the Issuer in respect of such notional number of Common Shares. All balances will be settled in cash. The Pershing Square Funds��counterparties for the swaps include entities related to Citibank, Nomura, Soci茅t茅 G茅n茅rale and UBS. The swaps do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership of any Common Shares that may be referenced in the swap contracts or Common Shares or other securities or financial instruments that may be held from time to time by any counterparty to the contracts.

Top 10 Bank Stocks For 2014: Webster Financial Corp (WBS)

Webster Financial Corporation (Webster), incorporated on September 10, 1986, is a bank holding company and financial holding company. Webster�� principal asset as of December 31, 2012, was Webster Bank, National Association (Webster Bank). Webster, through Webster Bank and various subsidiaries, delivers financial services to individuals, families and businesses primarily throughout southern New England and into Westchester County, New York. Webster provides business and consumer banking, mortgage lending, financial planning, trust and investment services through 167 banking offices, 293 automated teller machines (ATMs), telephone banking, mobile banking and its Internet Website www.websterbank.com. Webster also offers equipment financing, commercial real estate lending and asset-based lending across the Northeast. Webster Bank offers health savings accounts on a nationwide basis, through its HSA Bank division and its Internet Website www.hsabank.com. Webster�� operations are managed along four business segments: Commercial Banking, Retail Banking, Consumer Finance and Other. Other includes Health Savings Accounts (HSA) and Private Banking (including Webster Financial Advisors (WFA)).

Commercial Banking

The Commercial Banking segment includes middle market, asset-based lending, commercial real estate, equipment finance, and Government and not-for-profit banking. Webster�� Commercial Banking group provides lending, deposit and cash management services to middle market companies in its franchise territory. Additionally, it serves as a primary referral source to Wealth Management and Retail Banking.

Retail Banking

Retail Banking serves consumers and small businesses primarily throughout southern New England and into Westchester County, New York, with a distribution network of 167 banking offices and 293 owned ATMs, and a full range of Internet and mobile banking services. Retail Banking includes Webster�� branch network, Consumer deposits, Busin! ess and Professional Banking (BPB), Webster Investment Services (WIS) and the Customer Care Center.

Consumer Finance

Consumer Finance offers lending solutions for consumers primarily in southern New England and Westchester County, New York. Products include: residential mortgages, home equity loans and lines of credit, unsecured personal loans as well as credit card options.

Other

Other includes HSA Bank (HSA) and Private Banking. HSA Bank is a bank custodian of health savings accounts. These accounts are provided for high deductible health plans offered by employers or directly to consumers. Private Banking provides local full relationship banking that serves high net worth clients, not-for-profit organizations and business clients for asset management, trust, loan and deposit products and financial planning services.

Subsidiaries of Webster Financial Corporation

Webster�� direct subsidiaries as of December 31, 2012 included Webster Bank, Fleming, Perry & Cox, Inc., and Webster Licensing, LLC. Webster also owns all of the outstanding common stock of Webster Statutory Trust, an unconsolidated financial vehicle that has issued or may in the future issue trust preferred securities. On July 18, 2012, the Company completed the redemption at par of all the outstanding principal amount of Webster Capital Trust IV fixed to floating-rate trust preferred securities. Webster Bank's direct subsidiaries include Webster Mortgage Investment Corporation, Webster Business Credit Corporation (WBCC) and Webster Capital Finance, Inc. (WCF). Webster Bank is the primary source of retail activity within the consolidated Company. Webster Bank is the primary source of retail activity within the consolidated group. Webster Bank provides banking services through 167 banking offices, 293 owned ATMs, telephone banking, mobile banking and its Internet websites. Residential mortgage origination activity is conducted through Webster Bank. Webster Mortgage! Investme! nt Corporation is a passive investment subsidiary whose primary function is to provide servicing on passive investments, such as residential real estate and commercial mortgage real estate loans transferred from Webster Bank. Various commercial lending products are provided through Webster Bank and its subsidiaries to clients within the region from Westchester County, NY to Boston, MA. WBCC provides asset-based lending services. WCF provides equipment financing for end users of equipment. Additionally, Webster Bank has various other subsidiaries that are not significant to the consolidated Company.

Advisors' Opinion:
  • [By Marc Bastow]

    Bank holding and financial company Webster Bank (WBS) raised its quarterly dividend 33% to 20 cents per share payable June 16 to shareholders of record June 2.
    WBS Dividend Yield: 2.63%

  • [By Monica Gerson]

    Webster Financial (NYSE: WBS) is projected to report its Q3 earnings at $0.49 per share on revenue of $149.73 million.

    Wells Fargo & Company (NYSE: WFC) is estimated to report its Q3 earnings at $0.97 per share on revenue of $20.97 billion.

Top 10 Bank Stocks For 2014: Banco Santander Brasil SA (BSBR)

Banco Santander (Brasil) S.A. (Santander Brasil), incorporated on August 9, 1985, is a full-service bank in Brazil. The Bank operates its business along three segments: Commercial Banking, Global Wholesale Banking and Asset Management and Insurance. Through its Commercial Banking segment, the Bank offers traditional banking services, including checking and savings accounts, home and automobile financing, unsecured consumer financing, checking account overdraft loans, credit cards and payroll loans to mid- and high-income individuals and corporations (other than to its Global Banking and Markets clients). Its Global Wholesale Banking segment provides financial services and solutions to a group of approximately 700 local and multinational conglomerates, offering such products as global transaction banking, syndicated lending, corporate finance, equity and treasury. Through its Asset Management and Insurance segment, the Company manages fixed income, money market, equity and multi-market funds and offers insurance products complementary to its core banking business to its retail and small- and medium-sized corporate customers.

Lending Activities

As of December 31, 2010, the Bank�� total loans and advances to customers equaled R$160.6 billion (42.9% of its total assets). Net of allowances for credit losses, loans and advances to customers equaled R$151.4 billion as of December 31, 2010 (40.4% of its total assets). In addition to loans, it had outstanding R$93.5 billion as of December 31, 2010.

Substantially all of its loans are to borrowers domiciled in Brazil and are denominated in reais. Its commercial, financial and industrial loans include primarily loans to small and medium-sized enterprises (SMEs) in its Commercial Banking segment, and to Global Banking and Markets corporate and business enterprise customers in its Wholesale Global Banking segment. The principal products offered to SMEs in this category include revolving loans, overdraft facilities, installme! nt loans, working capital and equipment finance loans. Credit approval for SMEs is based on customer income, business activity, collateral coverage and internal and external credit scoring tools. Collateral on commercial, financial and industrial lending to SMEs generally includes receivables, liens, pledges, guarantees and mortgages, with coverage generally ranging from 100% to 150% of the loan value depending on the risk profile of the loan. Its Wholesale Global Banking customers are offered a range of loan products ranging from typical corporate banking products (installment loans, working capital and equipment finance loans) to more sophisticated products (derivative and capital markets transactions).

The Bank�� Real estate-construction loans include construction loans made principally to real estate developers that are SMEs and corporate customers in its Wholesale Global Banking Segment. Loans in this category are generally secured by mortgages and receivables, though guarantees may also be provided as additional security. Real estate-mortgage loans include loans on residential real estate to individuals. All loans granted under this category are secured by the financed real estate. Installment loans to individuals consist primarily of unsecured personal installment loans (including loans whose payments are automatically deducted from a customer�� payroll), revolving loans, overdraft facilities, consumer finance facilities and credit cards. Lease financing includes primarily automobile leases and loans to individuals. The vehicle financed acts as collateral for the particular loan granted.

Investment Activities

The Bank�� investments include Government securities-Brazil, Government securities-other countries and other debt securities. As of December 31, 2010, the book value of the investment securities was R$84.7 billion (representing 22.6% of its total assets). Brazilian government securities totaled R$55.8 billion, or 65.9% of the Bank�� investment! securiti! es as of December 31, 2010. As of December 31, 2010, the Bank held no securities of single issuers or related group of companies whose aggregate book or market value exceed 10% of stockholders��equity, other than Brazilian government securities, which represented 76.9% of its stockholders��equity.

Sources of Funds

The Bank offers its customers a variety of deposit products, such as current accounts (also referred to as demand deposits), which do not bear interest; traditional savings accounts, which earn the Brazilian reference rate for savings accounts (taxa referencial) plus 0.5% per month, as set by the federal government, and time deposits, which are represented by certificates of bank deposits (CDBs), which normally have a maturity of less than 36 months and earn interest at a fixed or floating rate. In addition, it accepts deposits from financial institutions as part of its treasury operations, which are represented by certificates of interbank deposit CDIs, and which earn the interbank deposit rate.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    Banco Santander (Brasil) SA (NYSE: BSBR) shares were also up, gaining 12.46 percent to $6.50 on Q1 results. The company reported Q1 recurring net income of 1.427 billion reais ($637 million).

  • [By Jonas Elmerraji]

     

     

    Nearest Resistance: $6.40��br>Nearest Support: $5.80��br>Catalyst: Brazil Elections

     

    Banco Santander Brasil (BSBR) is another Brazilian stock that's getting shoved lower on big volume following the country's election results. The Rousseff administration's willingness to step in and impart new rules on the private sector is the catalyst here. And Petrobras and Banco Santander Brasil aren't in a vacuum here; the Ibovespa index is down more than 3.4% overall as I write.

     

    The technical story in BSBR is pretty nasty here. Shares violated support at $6.40 back in early October, falling through that long-term price floor, and then confirming last week that it was now a resistance level. $5.80 looks like the next meaningful support level on the way down, but it's a weak one.

     

  • [By WWW.DAILYFINANCE.COM]

    www.blackcard.com Black cards are the most exclusive credit cards on the market, and these rare credit cards are in the pockets of some of the wealthiest citizens around the world. Here's what it takes -- and what you can get. 1. Eurasian Bank Diamond Card Featuring a 0.02-carat diamond surrounded by a golden heart design, the Eurasian Bank Diamond Card is a sign of wealth and elegance through and through. The black card requirements for this exclusive credit card is you have to be a member of the Eurasian bank in Kazakhstan, and you also have to have $300,000 or more in your bank account. 2. The Visa (V) Signature Card Visa's true top of the line card is the Visa Signature Card, which features some amazing perks like no preset spending limits; access to special sporting events and concert tickets; VIP access to entertainment venues like Broadway shows and musicals; travel accommodations at spas, hotels and with airlines; and special dining experiences. 3. The Chase (JPM) Sapphire Preferred Card For those who look for exclusivity but prefer not to bank with Visa or Amex (AXP), there is the Chase Sapphire Preferred Card. The Preferred Card is aimed at households in the United States earning at least $120,000 per year. Big perks include no preset spending limit and a strong rewards program for members. Other notable differences from other black card offerings include: Identity protection; a small $95 per year fee; enhanced travel rewards redemption points; rental insurance; travel protection insurance; emergency travel assistance and extended warranty protection for up to one year. 4. The Black Brazilian MasterCard (MA) from the Santander Group The Santander Group (BSBR) in Brazil offers the unlimited Brazilian Black MasterCard, which is only issued to members of its private bank with a certain undisclosed amount of funds in their accounts. Currently, it is one of the hottest cards in Latin America -- with only about 3,000 in circulation. Perks of the c

  • [By Rudy Martin]

    We are buying Banco Santander (Brasil) S.A. (BSBR) to gain broad additional exposure to the Brazilian.

    BSBR offers a full-service range of financial services, including individual and corporate banking. We also hope to benefit from the stock's 7.2% current indicated dividend yield.

Top 10 Bank Stocks For 2014: Golden Valley Bank (GVYB)

Golden Valley Bank is owned and operated commercial bank serving the needs of individuals and businesses in northern California. The Bank provides personal services, such as checking and savings and IRAs. The Bank�� business includes checking, savings, commercial lending, online banking and eDeposit.

The Bank provides business owners; commercial developers and investors, and residential builders and developers. Golden Valley Bank's business online banking service provides account management, bill pay and transactions services.

Advisors' Opinion:
  • [By CRWE]

    Today, GVYB remains (0.00%) +0.000 at $9.00 thus far (ref. google finance Delayed: 11:59AM EDT July 17, 2013).

    Golden Valley Bank headquartered in Chico, California previously reported June 30, 2013 financials. The company also announced their $.05 per share second quarter cash dividend.

    2nd Quarter 2013 Financial Highlights: Year to date net profit $683,911 compared to $514,030 year to date in 2012; Assets up $14.9 million to $136.7 million, or 12.2%, over the second quarter of 2012; Loans up $6.2 million to $89.5 million, or 7.4%, over the second quarter of 2012; Deposits up $14.6 million to $118.6 million, or 14%, over the second quarter of 2012

    The results of the Gravity Survey will be released once they are available

Top 10 Bank Stocks For 2014: Community Bank System Inc (CBU)

Community Bank System, Inc., incorporated on April 15, 1983, which wholly owns five subsidiaries: Community Bank, N.A. (the Bank), Benefit Plans Administrative Services, Inc. (BPAS), CFSI Closeout Corp. (CFSICC), First of Jermyn Realty Company, Inc. (FJRC) and Town & Country Agency LLC (T&C). The Bank operates as a community bank providing a range of banking and financial services to retail, commercial, and municipal customers. As of December 31, 2012, the Bank operates 179 full-service branches throughout 35 counties of Upstate New York, where it operates as Community Bank, N.A. and five counties of Northeastern Pennsylvania, where it is known as First Liberty Bank & Trust, offering a range of commercial and retail banking services. BPAS provides administration, consulting and actuarial services to sponsors of employee benefit plans. In December 2013, the Company announced that it has acquired eight branch-banking locations across its Northeast Pennsylvania markets from Bank of America, N.A.Five of the branches are located in Luzerne County, one is located in Lackawanna County and two are located in Carbon County.

On July 20, 2012, the Bank completed its acquisition of 16 retail branches in Central, Northern and Western New York from HSBC Bank USA, N.A. (HSBC), acquiring approximately $106 million in loans and $697 million of deposits. On September 7, 2012, it completed its acquisition of three branches in Western New York from First Niagara Bank, N.A. (First Niagara), acquiring approximately $54 million of loans and $101 million of deposits.

Lending Activities

As of December 31, 2012, the Bank�� loan portfolio included consumer mortgage loans, business lending, Consumer indirect, Consumer direct and Home equity. Consumer indirect and direct loans consist of personal loans originated both in the branch network and in automobile, marine and recreational vehicle dealerships. Approximately 68% of loans outstanding as of December 31, 2012, were made to consumers ! borrowing on an installment, line of credit or residential mortgage loan basis. The consumer mortgage portion of the Company�� loan portfolio is comprised of fixed (98%) and adjustable rate (2%) residential lending and includes no exposure to subprime, Alt-A or other higher-risk mortgage products. The combined total of general-purpose business lending, including agricultural-related and dealer floor plans, as well as mortgages on commercial property, is characterized as the Company�� business lending activity.

Investment Activities

As of December 31, 2012, the Bank�� investment securities included held-to-maturity, available-for-sale and Other securities. As of December 31, 2012, its held-to-maturity portfolio included U.S. Treasury and agency securities, Obligations of state and political subdivisions, Government agency mortgage-backed securities, Corporate debt securities and Other securities. Its Other Securities included Federal Home Loan Bank common stock, Federal Reserve Bank common stock and Other equity securities.

Sources of Funds

The Bank utilizes a variety of funding sources to support the earning asset base. Overall funding is comprised of three primary sources that possess a variety of maturity, stability, and price characteristics: deposits of individuals, partnerships and corporations (IPC deposits), municipal deposits that are collateralized for amounts not covered by FDIC insurance (public funds) and external borrowings. The various types of deposits offered by the Bank include Noninterest checking deposits, Interest checking deposits, Regular savings deposits, Money market deposits and Time deposits. Borrowing sources for the Company include the Federal Home Loan Bank of New York (FHLBNY) and Federal Reserve Bank of New York, as well as access to the brokered certificate of deposit (CD) and repurchase markets through relationships with primary market security dealers.

Subsidiary Activities

The Compan! y�� sub! sidiary, BPAS owns three subsidiaries, Benefit Plans Administrative Services LLC (BPA), a provider of defined contribution plan administration services; Harbridge Consulting Group LLC (Harbridge), a provider of actuarial and benefit consulting services, and Hand Benefits & Trust Company (HB&T), a provider of Collective Investment Fund administration and institutional trust services. HB&T owns two subsidiaries, Flex Corp. (Flex), a provider of administration, servicing and marketing of various flexible employee benefit programs and Hand Securities, Inc. (HSI), an introducing broker dealer. The Company also wholly owns two unconsolidated subsidiary business trusts formed for the purpose of issuing mandatorily redeemable preferred securities.

The Bank owns subsidiaries, such as CBNA Insurance Agency, Inc. (CBNA Insurance), CBNA Preferred Funding Corporation (PFC), CBNA Treasury Management Corporation (TMC), Community Investment Services, Inc. (CISI), First Liberty Service Corp. (FLSC), Nottingham Advisors, Inc. (Nottingham), Brilie Corporation (Brilie), and Western Catskill Realty, LLC (WCR). CBNA Insurance is a full-service insurance agency offering primarily property and casualty products. PFC primarily acts as an investor in residential real estate loans. TMC provides cash management, investment, and treasury services to the Bank. CISI provides broker-dealer and investment advisory services. FLSC provides banking-related services to the Pennsylvania branches of the Bank. Nottingham provides asset management services to individuals, corporate pension and profit sharing plans, and foundations. Brilie and WCR are inactive companies.

Advisors' Opinion:
  • [By GURUFOCUS]

    Community Bank System Inc. (CBU) operates as the bank holding company for Community Bank, N.A. that provides banking and financial services to retail, commercial, and municipal customers. August 21st the company increased its quarterly dividend 3.7% to $0.28 per share. The dividend is payable October 10, 2013 to shareholders of record as of September 16, 2013. The yield based on the new payout is 3.3%.

Top 10 Bank Stocks For 2014: Julius Baer Gruppe AG (BAER)

Julius Baer Gruppe AG (the Group) is a Switzerland-based private banking group, with an exclusive focus on servicing and advising private clients and independent asset managers. The Group has a global presence with approximately 50 locations in more than 25 countries and jurisdictions. Julius Baer Gruppe AG was established through spin off from Julius Baer Holding AG�� businesses into two independent entities, namely the Company, together with its subsidiaries, comprising Bank Julius Baer & Co Ltd as its principal operating entity, and GAM Holding, together with its subsidiaries, comprising GAM and the Julius Baer-branded asset management business, which includes the private label funds business that formerly was part of Julius Baer Holding Ltd�� Bank Julius Baer segment. The Group diversifies its operations into geographical segments, including Switzerland, rest of Europe, Americas, and Asia and Other Countries. Advisors' Opinion:
  • [By Corinne Gretler]

    Julius Baer Group Ltd. (BAER) rallied 5.7 percent to 42.04 francs. Switzerland�� third-biggest wealth manager said increased client trading boosted margins as it integrated Merrill Lynch businesses acquired from Bank of America Corp. last year. The gross margin, which reflects how much the bank makes in revenue on managed client assets, rose to 102 basis points in the first half, from 98 basis points in the year-earlier period.